Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.65 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010554 | 1.00 | LTA4H (0.65) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL30010207 | 1.00 | LTA4H (0.65) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL29577413 | 0.99 | LTA4H (0.66) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL30011211 | 0.98 | LTA4H (0.65) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL29577006 | 0.98 | LTA4H (0.65) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL29578686 | 0.98 | LTA4H (0.65) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL30052812 | 0.97 | KMT2A (0.64) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL30288025 | 0.97 | KMT2A (0.64) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL2182644 | 0.97 | LTA4H (0.69) | LTA4HACEMMEALOX15KMT2A | |
| SCHEMBL31477993 | 0.97 | LTA4H (0.69) | LTA4HACEMMEALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | LTA4H 3533/4885ACE 1190/4885MME 824/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | LTA4H 1299/4885ACE 486/4885MME 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.